Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1631574 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $5.81Day −1.36%Mkt cap $1.1B1Y −30.2%Off 52W high −73.3%Vol (1Y) 168.8%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,690 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest8.8% of sh out |
| Days to cover6.3d |
| 13F net flow (QoQ)−1.61% |
| Top-10 13F concentration60.2% |
| Next report (est.)2026-08-02 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$42.7M |
| Earnings (TTM)-$183.6M |
| ROE−56.2% |
| Net margin−478.3% |
| Sales growth 3Y127.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−65.8% |
| 1Y−30.2% |
| 3Y+33.0% |
| 5Y+0.9% |
| 10Y−69.9% |
| Since incept. (ann.)−9.0% |
Total return through 2026-07-29 · series begins 2015-11-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)168.8% |
| Ann. volatility (3Y)126.9% |
| Sharpe (1Y)0.37 |
| Sharpe (3Y)0.58 |
| Max drawdown (1Y)−73.4% |
| Max drawdown (3Y)−73.4% |
| Beta (3Y vs SPY)0.50 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 27.0M | $196M | 14.02% | +48.2% |
| GSK plc | 18.2M | $132M | 9.48% | +0.0% |
| BlackRock, Inc. | 14.1M | $102M | 7.34% | +11.6% |
| MAVERICK CAPITAL LTD | 10.2M | $74M | 5.28% | +9.5% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.7M | $63M | 4.52% | +17.5% |
| Driehaus Capital Management LLC | 5.4M | $39M | 2.82% | −17.5% |
| FEDERATED HERMES, INC. | 5.3M | $39M | 2.76% | +12.1% |
| FMR LLC | 5.2M | $38M | 2.70% | −65.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-28 | −$0.13 | — | $38.2M | +316.9% |
| 2025-09-30 | 2025-11-10 | −$0.32 | — | — | — |
| 2025-06-30 | 2025-07-30 | −$0.31 | — | $8.7M | −55.8% |
| 2025-03-31 | 2025-05-08 | −$0.29 | — | $9.2M | −26.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-02 is ESTIMATED from filing cadence (median gap 96d) — not company-confirmed.
